Related references
Note: Only part of the references are listed.Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
Lisa Aniek de Jong et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Economic evaluation of the use of non-vitamin Koral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands
Naoual Bennaghmouch et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2019)
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France
Shuk-Li Collings et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2018)
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries
Siyang Peng et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013
Jean Dallongeville et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France
Francois-Emery Cotte et al.
EUROPACE (2016)
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2016)
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
Jean-Pierre Bassand et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
Ying Jiao Zhao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis
Patrick Blin et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
Craig I. Coleman et al.
PLOS ONE (2016)
A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
Hedwig M. Blommestein et al.
PHARMACOECONOMICS (2015)
APPRAISING THE COST OF PHYSICIAN VISITS AND TECHNICAL PROCEDURES IN FRANCE IN THE AGE OF OPEN DATA
A. Sherwood et al.
VALUE IN HEALTH (2015)
Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
Thitima Kongnakorn et al.
CLINICAL DRUG INVESTIGATION (2015)
Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study
Laurent Fauchier et al.
OPEN HEART (2015)
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
Julie Chevalier et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2014)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
CIRCULATION (2014)
Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Irene Savelieva et al.
CLINICAL CARDIOLOGY (2014)
Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France
Francois-Emery Cotte et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2014)
HEALTH UTILITY IN PATIENTS FOLLOWING CARDIOVASCULAR EVENTS
R. D. Pockett et al.
VALUE IN HEALTH (2014)
QUALITY OF LIFE DECREMENTS AFTER STROKE
S. Dewilde et al.
VALUE IN HEALTH (2014)
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
T. Lanitis et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
Quality of life after TIA and stroke Ten-year results of the Oxford Vascular Study
Ramon Luengo-Fernandez et al.
NEUROLOGY (2013)
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
Brendan L. Limone et al.
PLOS ONE (2013)
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Ajay K. Kakkar et al.
PLOS ONE (2013)
Assessing the Risk of Bleeding in Patients With Atrial Fibrillation The Loire Valley Atrial Fibrillation Project
Gregory Y. H. Lip et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2012)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
EM Hylek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community - The Framingham Heart Study
TJ Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
